Ketolide-Streptogramin Group of Antibiotics in Staphylococci

Ketolide-Streptogramin Group of Antibiotics in Staphylococci

Journal of Antimicrobial Chemotherapy (2000) 46, 941–949 JAC Patterns of phenotypic resistance to the macrolide-lincosamide- ketolide-streptogramin group of antibiotics in staphylococci J. M. T. Hamilton-Miller* and Saroj Shah Department of Medical Microbiology, Royal Free and University College, Royal Free Campus, London NW3 2PF, UK Phenotypes of resistance to the macrolide-lincosamide-ketolide-streptogramin (MLKS) group of antibiotics have been determined in 540 clinical isolates of staphylococci (210 Staphylo- coccus aureus and 330 coagulase-negative species). Results of disc diffusion tests using erythromycin A, oleandomycin, rokitamycin, clindamycin, telithromycin, quinupristin and dalfo- pristin delineated four main groups corresponding to those defined classically using erythro- mycin and clindamycin only, but with sub-divisions. Resistance to erythromycin was more common in coagulase-negative strains (56%) than in S. aureus (16%); telithromycin, clinda- mycin, quinupristin–dalfopristin and rokitamycin were active against >97% of S. aureus strains and >88% of the coagulase-negative strains. The commonest resistance phenotype was ‘inducible MLSB’ (12% in S. aureus, 31% in coagulase-negative strains); this group could be divided in terms of the different inducing abilities of erythromycin and oleandomycin. ‘Consti- tutive MLSB’ and ‘MS’ phenotypes were more often found in coagulase-negative strains (11 and 13%, respectively) than in S. aureus (2 and 1%). Novel phenotypes were found during the isolation of constitutively resistant mutants from inducible strains, and of resistant mutants from ‘MS’ strains. This extended phenotyping scheme has revealed further complexities and evolutionary possibilities in patterns of resistance to this group of antibiotics. Introduction among a large number of unselected staphylococci isolated from patients in a university hospital, and to investigate Interest in the macrolide antibiotics has increased greatly how these resistance mechanisms affected susceptibility during the last decade. This was a consequence firstly of to antibiotics related to erythromycin A, namely another chemical modifications to the ring structure of erythromycin 14-membered macrolide (oleandomycin), a 16-membered A resulting in newer macrolides such as azithromycin, macrolide (rokitamycin), a lincosamide (clindamycin), a clarithromycin and roxithromycin,1,2 and secondly of the ketolide (telithromycin) and representatives of the A and synthesis of the ketolides,3 in which significant alterations B components of the streptogramins (quinupristin and have been made to the sugar side chains. The newer macro- dalfopristin), alone and in combination. lides have remarkable pharmacokinetic properties, enlarg- ing their spectrum compared with the archetypal macrolide erythromycin A, but all the resistance mechanisms that Materials and methods operate against the latter also apply to the former. Thus, Bacterial strains there is complete cross-resistance. On the other hand, keto- lides do not induce the enzyme responsible for the most A total of 540 strains of individual staphylococci, compris- common form of resistance to erythromycin, the so-called ing 210 Staphylococcus aureus and 330 coagulase-negative 4 ‘inducible MLSB’ phenotype. Therefore ketolides, in con- staphylococci (CNS), isolated in the Diagnostic Micro- trast to the newer macrolides, remain active against many biology Laboratory of The Royal Free Hospital, London, erythromycin-resistant strains.5 UK, during June 1998, were identified by their colonial The purpose of the present study was to determine the appearance, Gram’s staining and production of catalase. incidence of various types of erythromycin resistance S. aureus and CNS were differentiated using DNase and *Corresponding author. Tel: ϩ44-20-7794-0500; Fax: ϩ44-20-7435-9694; E-mail: [email protected] 941 © 2000 The British Society for Antimicrobial Chemotherapy J. M. T. Hamilton-Miller and S. Shah Staphaurex. CNS were identified where appropriate using antibiotics to be observed with a minimum amount of API Staph kits. repetition. The origin of each strain was checked by patient’s name Zone sizes and their shapes were read after overnight and hospital number, and possible duplicate strains incubation, and then again after a further 24 h. If the nature excluded. For the methicillin-resistant strains, only one of of a specific interaction was not clear, the individual test each clonal type was included in the test population. was set up again in 90 mm plates, with the distances between discs being varied as appropriate. Zones were interpreted according to their size and Antibiotics shape, as indicating sensitive or resistant, the latter being Telithromycin (HMR 3647) was given by Hoechst Marion inducible if a ‘D’-shaped zone was observed (the com- Roussel (Romainville, France); Synercid (RP 59500, seven pound on the left being the inducer). Synergy was recorded parts quinupristin, three parts dalfopristin), dalfopristin if there was an extension of inhibition zone between two (RP 54476) and quinupristin (RP 57669), each as the discs. The presence of satellite colonies within inhibition methane sulphonate, were given by Rhone-Poulenc Rorer zones, and other evidence for the existence of sub-popula- (Collegeville, PA, USA); erythromycin BP free base was tions (e.g. some degree of ‘target zone’ formation) as well given by Lilly Industries (Basingstoke, UK); rokitamycin as unusual shapes of zones were noted. was given by ISF SpA (Milan, Italy); lincomycin hydro- Phenotypes were denoted by abbreviations of antibiotic chloride and oleandomycin phosphate were purchased class to which a strain was resistant: M, erythromycin; A, from Sigma (Poole, UK). Erythromycin was dissolved in oleandomycin; L, clindamycin; SA, dalfopristin; SB, quinu- ethanol, the other compounds in water. pristin; K, telithromycin; Mac, rokitamycin. Discs containing oleandomycin 15 ␮g were purchased When resistance was inducible by erythromycin, i was from Mast Laboratories (Bootle, UK), and erythromycin prefixed. Thus, for example, the classical ‘inducible MLSB’ ␮ ␮ 15 g and clindamycin 2 g from Unipath Laboratories phenotype is denoted here as M/i(LKSBMac), and the ␮ (Basingstoke, UK). Discs containing Synercid 15 g and classical ‘constitutive MLSB’ phenotype is MLKSBMac. telithromycin 15 ␮g were given by Rhone-Poulenc Rorer We also used the 13 disc method to determine the R-D (Antony, France) and Hoechst Marion Roussel, phenotypes of five strains (two MRSA, three Staphylo- respectively. Discs containing 15 ␮g of either rokitamycin, coccus haemolyticus) that had previously shown anomalous dalfopristin or quinupristin were made as required by susceptibilities to telithromycin.5 treating Whatman AA discs with the appropriate antibiotic solution. Chemicals These were obtained from Sigma (Poole, UK). Media Nutrient agar (NA), Mueller–Hinton agar (MHA) and broth (MHB) were from Unipath. ‘Blood agar’ was Colum- bia agar (Mast) ϩ 5% whole horse blood. Susceptibility testing All 540 strains were tested by the breakpoint method against erythromycin (0.5 and 4 mg/L), lincomycin (1 and 2 mg/L) and Synercid (1 mg/L), on MHA inoculated with 104 cfu, incubated for 24 h in air. The 215 strains resistant to erythromycin and the five sensitive to erythromycin but resistant to lincomycin were then screened by a disc diffusion method. An aqueous sus- pension of bacterial growth from blood agar was adjusted Figure 1. The 13 disc screening method for investigating activi- to McFarland 0.5, and inoculated by swab on MHA ties of and interactions between MLKSMac antibiotics. Top row: ␮ (60 L in a plate of diameter 140 mm). Each plate was set Synercid (SYN), rokitamycin (R), clindamycin (CD2), dalfo- with 13 discs (centres 2 cm apart) as shown in Figure 1. This pristin (D). Middle row: clindamycin, oleandomycin (OL), arrangement allowed both the sensitivity pattern to indi- erythromycin (E), telithromycin (T), oleandomycin. Bottom row: vidual compounds and interactions between the various quinupristin (Q), dalfopristin, quinupristin, rokitamycin. 942 Phenotypic staphylococcal resistance to MLS and ketolides MIC determinations were made following the NCCLS For technical reasons it was not possible to test for dalfo- agar dilution method.6 pristin inactivation under these conditions. Selection of resistant mutants Results Cultures in MHB were spun down and resuspended at Sensitivity to individual agents 10ϫ original concentration. A viable count was performed, and 0.1 mL (c. 109 cfu) was spread on MHA containing Sensitivity patterns are shown in Table I. CNS were signifi- 1.2 mg/L telithromycin (i.e. at least 20 ϫ MIC) and colonies cantly more often resistant to erythromycin, telithromycin, counted after 48 h incubation. The proportion of cells able clindamycin, quinupristin or rokitamycin than were S. Ͻ to grow was calculated, and their phenotypes determined aureus strains (P 0.01 by chi-squared test). Only five by the 13 disc method described above. strains (two Staphylococcus epidermidis, two Staphylo- coccus sciuri and one Staphylococcus simulans) were resistant to dalfopristin (MIC 32 or 64 mg/L). All 540 Reversal of resistance strains tested were sensitive to Synercid, despite two (the S. epidermidis mentioned above, nos 152 and 538) being (i) Doubling dilutions of ethidium bromide in MHA were resistant to both components (Figure 2). spot-inoculated with strains under test, and incubated overnight. For each strain, sub-culture was made from the 0.5 ϫ MIC

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    10 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us